Also yesterday’s post approval was day 1 of the journey. The...

First 168 Last

Share
Profile

Follow
Upthefog

1,709 Posts.

612

01/11/18

08:10

Post #: 36344133
Share

Originally posted by HonyakuKonyaku ↑

Originally posted by razi
True that we anxiously waited (for what seemed like an eternity) for CFDA & exhaled mightily when it seemed to arrive. And, yes, probably most of us were disappointed that the SP rose "only" 10% when trading resumed (I certainly was, having seen that it opened at 0.45 upon going to sleep & then seeing a green 0.375 upon awakening...which almost had a reddish tint to it). That said, it's apt to be a long & winding road ahead...requiring considerable patience & continued belief in the essential nature/vision of the what GMV strives to offer. Unlike the recreational/faddish "toys" VR & Kinect, the Prizma/Patch & call centers address a clear universal health need that could/should appeal to almost anyone, anywhere. CFDA was never the end game...just a MAJOR obstacle along the way that needed to be overcome. And now that the path has been cleared, generating revenue will have to follow if the venture is to succeed. That could take MANY months to happen (or perhaps never). Big-agenda startups, like ours, typically need more time than others to unfold...but things DO seem to be progressing in the right direction -- even if more slowly than what most of us would prefer. If long-term, like me, I suggest trying to chill, appreciating the not inconsequential progress already made, retaining faith in the concept/products/services & in Dr. Geva's knowing how to get the job done. Best wishes to all...
Thanks for the measured replies. I was probably a bit out of line with my post. Nasdaq had a good session so maybe there will be a bit more appetite for risk today.

Expand

Also yesterday’s post approval was day 1 of the journey. The tale of the tape will be the next 6 mths. Ongoing patience still important. Good luck all

GMV Price at posting: 37.5¢ Sentiment: Buy Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

EBR

EBR reaches review milestone for wireless cardiac pacing device

VYS

Vysarn acquires Waste Water Services Pty Ltd for $7.5M; WWS to become subsidiary as expansion continues

HVN

Consumers cautious according to Harvey Norman, as profit slumps 35% in FY24

Results wrap: Austal, TPG Telecom and Downer

Consumer Staples Shine Amid Retail Slump – Key Stocks to Watch

HLX

Helix investor makes partial takeover bid, proposing board changes

TBN

Tamboran kicks off Shenandoah South pilot project with SS-2H well spud

LLC

Lendlease sells off US east coast construction operations in latest global divestment push

PYC

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

CYM

WA Nifty copper project steps closer to restart with Cyprium Metals inking $40M loan from Glencore